Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01844661|
Recruitment Status : Completed
First Posted : May 1, 2013
Last Update Posted : February 19, 2016
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Instituto de Salud Carlos III
Information provided by (Responsible Party):
Manuel Ramírez, MD PhD, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||January 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Ruano D, López-Martín JA, Moreno L, Lassaletta Á, Bautista F, Andión M, Hernández C, González-Murillo Á, Melen G, Alemany R, Madero L, García-Castro J, Ramírez M. First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors. Mol Ther. 2020 Apr 8;28(4):1033-1042. doi: 10.1016/j.ymthe.2020.01.019. Epub 2020 Jan 21.